Stitz L, Baenziger J, Pircher H, Hengartner H, Zinkernagel R M
J Immunol. 1986 Jun 15;136(12):4674-80.
The susceptibility of cytotoxic effector lymphocytes and their induction to in vivo or in vitro treatment with rabbit anti-neutral glycolipid ganglio-N-tetraosylceramide (anti-ASGM1) antiserum was investigated. Intravenous injection of anti-ASGM1 antiserum eliminated measurable natural killer (NK) cell activity in spleen cells of mice infected for 5 days with Vaccinia virus, or for 8 days with lymphocytic choriomeningitis virus (LCMV) if injected 24 hr prior to testing. In addition, this treatment lowered measurable virus-specific cytotoxic T cell activity by 60 to 95%. Virus-specific cytotoxic T cell and NK cell activity generated during a primary infection in vivo was also sensitive to treatment in vitro with anti-ASGM1 antiserum (1/300 to 1/600 dilution) plus rabbit complement at a dilution of 1/15 (20 to 50% cell death, more than 30-fold decrease of cytotoxic activity); in vitro treatment with rabbit complement alone often enhanced NK and cytotoxic T cell activity slightly. In vivo treatment with anti-ASGM1 before primary immunization decreased generation of primary CTL only if high doses of anti-ASGM1 antiserum were injected twice. Antiviral T cells generated during secondary stimulation in vitro and alloreactive cytotoxic T cells from a mixed lymphocyte culture were resistant to treatment in vitro with anti-ASGM1 plus complement at the end of the culture period. Treatment in vitro of in vivo-primed responder spleen cells with anti-ASGM1 plus complement before their addition to a secondary restimulation culture resulted in complete inhibition of a secondary antiviral cytotoxic T cell response. In vivo treatment with anti-ASGM1 24 hr before their spleen cells were harvested and restimulated in vitro significantly reduced the virus-specific T cell activity of mice that had been immunized with virus several weeks previously. A cloned T cell line exclusively exerting NK-like activity was resistant, and two cloned virus-specific cytotoxic T cell lines were susceptible to treatment with anti-ASGM1 plus complement in vitro. These results caution the general use of rabbit anti-ASGM1 as a marker to distinguish NK from CTL cells; they indicate a possible relationship between NK and CTL cells and suggest that in vitro culture of lymphocytes may alter or select the cell surface expression or availability of the ASGM1 marker(s).
研究了细胞毒性效应淋巴细胞对兔抗中性糖脂神经节苷脂-N-四糖神经酰胺(抗ASGM1)抗血清体内或体外处理的敏感性及其诱导情况。静脉注射抗ASGM1抗血清可消除感染痘苗病毒5天或感染淋巴细胞性脉络丛脑膜炎病毒(LCMV)8天的小鼠脾细胞中可检测到的自然杀伤(NK)细胞活性(如果在检测前24小时注射)。此外,这种处理使可检测到的病毒特异性细胞毒性T细胞活性降低了60%至95%。在体内初次感染期间产生的病毒特异性细胞毒性T细胞和NK细胞活性也对抗ASGM1抗血清(1/300至1/600稀释)加兔补体(1/15稀释)的体外处理敏感(细胞死亡20%至50%,细胞毒性活性降低超过30倍);单独用兔补体进行体外处理通常会轻微增强NK细胞和细胞毒性T细胞活性。在初次免疫前用抗ASGM1进行体内处理,只有在高剂量抗ASGM1抗血清注射两次时才会减少初次CTL的产生。在体外二次刺激期间产生的抗病毒T细胞以及来自混合淋巴细胞培养的同种异体反应性细胞毒性T细胞在培养期结束时对抗ASGM1加补体的体外处理具有抗性。在用抗ASGM1加补体对体内致敏的反应性脾细胞进行体外处理后,再将其加入二次再刺激培养物中,会导致二次抗病毒细胞毒性T细胞反应完全受到抑制。在收获脾细胞并在体外进行再刺激前24小时用抗ASGM1进行体内处理,可显著降低几周前用病毒免疫过的小鼠的病毒特异性T细胞活性。一个仅发挥NK样活性的克隆T细胞系具有抗性,而两个克隆的病毒特异性细胞毒性T细胞系在体外对抗ASGM1加补体的处理敏感。这些结果警示了将兔抗ASGM1作为区分NK细胞和CTL细胞标记物的普遍应用;它们表明NK细胞和CTL细胞之间可能存在关系,并提示淋巴细胞体外培养可能会改变或选择ASGM1标记物的细胞表面表达或可用性。